Study Description
This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.
The investigators will collect safety information and evaluate effectiveness in patients who are prescribed Beovu ® Injection, Beovu ®Prefilled Syringe (brolucizumab) in the approved indication after receiving informed consent over a period of 12 weeks. In addition, longer-term data (24 weeks, optionally 36 weeks) will be collected.
Interventions
brolucizumab
Eligibility Criteria
Inclusion Criteria:
Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per approved local product information
Patients who consent to participate in the study after the purpose and nature of the study have clearly explained to them (written informed consent)
Exclusion Criteria:
Contraindications as per local prescribing information 1) Hypersensitivity to the active substance or to any of the excipients. 2) Active or suspected ocular or periocular infection. 3) Active intraocular inflammation.
Patients participating in other investigational drug trial
Study Location
Novartis Investigative Site
Recruiting
Suwon-si,Gyeonggi-do,16499,Korea, Republic of
Novartis Investigative Site
Recruiting
Goyang si,Gyeonggi Do,10380,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,04763,Korea, Republic of
Novartis Investigative Site
Recruiting
Busan,48064,Korea, Republic of
Novartis Investigative Site
Recruiting
Pusan,614 735,Korea, Republic of
Novartis Investigative Site
Recruiting
Taegu,41944,Korea, Republic of
Novartis Investigative Site
Recruiting
Guri-si,Gyeonggi-do,471-701,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,05368,Korea, Republic of
Novartis Investigative Site
Recruiting
Busan,602739,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,01000,Korea, Republic of
Novartis Investigative Site
Recruiting
Gwangju,61489,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,06273,Korea, Republic of
Novartis Investigative Site
Recruiting
Daegu,Dalseo Gu,42602,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,02841,Korea, Republic of
Novartis Investigative Site
Recruiting
Gwangju,61932,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,06351,Korea, Republic of
Novartis Investigative Site
Recruiting
Daegu,705 718,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03080,Korea, Republic of
Novartis Investigative Site
Recruiting
Iksan Si,Jeonlabuk Do,570-711,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,07301,Korea, Republic of
Novartis Investigative Site
Recruiting
Daegu,705703,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03722,Korea, Republic of
Novartis Investigative Site
Recruiting
Incheon,22332,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,07441,Korea, Republic of
Novartis Investigative Site
Recruiting
Daejeon,Korea,35015,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,04401,Korea, Republic of
Novartis Investigative Site
Recruiting
Busan,47524,Korea, Republic of
Novartis Investigative Site
Recruiting
Jeju,63206,Korea, Republic of
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.